Anemia, or insufficient production of red blood cells (RBC), affects close to 3.5 million people in the U.S. The gene D930015E06Rik is highly expressed during the later stages of erythroid terminal differentiation, which is the process whereby RBC are produced in the body. Previous studies achieved cloning and expression of a portion of the coding sequence of D930015E06Rik cDNA as a thioredoxin fusion protein in E. coli. The recombinant partial D930015E06Rik fusion protein was cleaved from thioredoxin and reacted successfully with a goat anti-rabbit D930015E06Rik antibody that was generated from the recombinant D930015E06Rik fusion protein. This antibody is currently being used in experiments to document expression of the wild type D930015E06Rik protein in the Friend Virus Anemia cells ( a primary cell culture model that model that mimics ETD), as well as in continuous murine erythroleukemia (MEL) cell line. MEL cells can be induced to undergo a limited form of ETD, but allow for generation of stable transfected cell lines. Short hairpin RNA (shRNA) specific for D930015E06Rik are being generated and will be transfected into the MEL cells to knock down expression of the wild type D930015E06Rik. Knock down of D930015E06Rik during ETD will be assessed using western blot analysis as well as quantitative polymerase chain reaction (qPCR). Effects of D930015E06Rik knock down on the ETD of MEL cells will be assessed in the hope of determining the function of D930015E06Rik in this process, which may contribute to improvement of therapies for anemia.